Results 91 to 100 of about 667,198 (303)
Background In the EDITA trial, patients with systemic sclerosis (SSc) and mild pulmonary vascular disease (PVD) treated with ambrisentan had a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP ...
Panagiota Xanthouli +10 more
doaj +1 more source
This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.
Yuxi Luo +10 more
wiley +1 more source
Cellular senescence in adult pulmonary hypertension: current state and future challenges
Pulmonary hypertension (PH) is a life-threatening disease increasingly being diagnosed in the elderly population, marked by vascular injury, excessive vasoconstriction and progressive remodelling of the pulmonary arteries (PAs).
Sarah-Eve Lemay +6 more
doaj +1 more source
Inoperable chronic thromboembolic pulmonary hypertension treated with riociguat: A case study
A 51-year-old woman presented with a one-year history of progressive dyspnea, WHO functional class III-IV and exercise-related syncope. Transthoracic echocardiography and computed tomography pulmonary angiography were performed, leading to a diagnosis of
Carlos Ortiz-Bautista +4 more
doaj +1 more source
Clinical Utility of Echocardiography in Former Preterm Infants with Bronchopulmonary Dysplasia. [PDF]
BackgroundThe clinical utility of echocardiography for the diagnosis of pulmonary vascular disease (PVD) in former preterm infants with bronchopulmonary dysplasia (BPD) is not established.
Fineman, Jeffrey R +6 more
core +1 more source
Pediatric Pulmonary Hypertension
Pulmonary hypertension (PH) is a rare disease in newborns, infants, and children that is associated with significant morbidity and mortality. In the majority of pediatric patients, PH is idiopathic or associated with congenital heart disease and rarely is associated with other conditions such as connective tissue or thromboembolic disease.
Ivy, D Dunbar +11 more
openaire +5 more sources
Legumain (LGMN) is upregulated in macrophages during sarcoid‑like granuloma formation. Macrophage‑derived LGMN binds to integrin αvβ3 and suppresses mTORC1/STAT1 signaling to restrain M1 macrophage polarization. Intratracheal delivery of lipid nanoparticles carrying Lgmn plasmid DNA (pDNA) elevates LGMN expression and effectively attenuates pulmonary ...
Mengyuan Liu +12 more
wiley +1 more source
The role of endothelin-1 in pulmonary arterial hypertension. [PDF]
Pulmonary arterial hypertension (PAH) is a rare but debilitating disease, which if left untreated rapidly progresses to right ventricular failure and eventually death. In the quest to understand the pathogenesis of this disease differences in the profile,
Chester, AH, Yacoub, MH
core +1 more source
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a disease of the small pulmonary arteries characterized by vascular narrowing and increased pulmonary vascular resistance, which eventually leads to right ventricular failure. Vasoconstriction, vascular proliferation, remodeling of the pulmonary vessels, and thrombosis are all contributing factors to the increased ...
Azad, Raiesdana, Joseph, Loscalzo
openaire +2 more sources
Bimodal modulation of nitric oxide in endothelial cells is achieved by light‐sensitive polymer nanoparticles. In dark, P3HT/PEDOT:PSS NPs boost intracellular ·NO, upregulate both endothelial and induced nitric oxide synthase, and drive a metabolic shift toward glycolysis.
Camilla Marzuoli +12 more
wiley +1 more source

